|View printer-friendly version|
Spring Bank Pharmaceuticals Reports 2018 Fourth Quarter and Full-Year Financial Results and Corporate Highlights
Conference Call to be Held at
“Spring Bank made significant progress in 2018 on multiple fronts, particularly the continued advancement of inarigivir for the treatment of chronic hepatitis B (HBV). We expanded our HBV clinical collaboration with
Mr. Driscoll further noted, “We are also advancing SB 11285, our novel, second-generation STING (Stimulator of INterferon Genes) agonist compound with the plan to initiate a Phase 1/2 trial in certain cancers in mid-2019. We are currently on track to submit an IND application for SB 11285 in the second quarter of 2019, which if approved, could result in SB 11285 being the first intravenously-administered STING agonist product candidate to enter clinical development. As we first disclosed at our Spring Bank R&D Day in December, we continue to make good progress in the advancement of our three new early research programs utilizing our small molecule nucleic acid chemistry platform, including a novel platform of STING antagonists, chiral antisense compounds against the HBx gene and next-generation RIG-I agonists for potential immuno-oncology uses.”
Mr. Driscoll concluded, “In
Potential 2019 Milestones
2018 Highlights and Recent Business Developments
Year-End and Fourth Quarter Financial Results
A replay of the call may be accessed by visiting Spring Bank’s website.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether the results of the company’s trials will warrant submission for approval from the
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
Source: Spring Bank Pharmaceuticals, Inc.